Peroxisome proliferator–activated receptor α (PPAR α) is a nuclear receptor of clinical
interest as a drug target in various metabolic disorders. PPAR α also exhibits marked anti …

The peroxisome proliferator-activated receptors (PPAR-α, PPAR-β/δ, and PPAR-γ) are
members of the nuclear receptor super-family, acting as ligand-inducible transcription …

In mammalian cells, two cellular organelles, mitochondria and peroxisomes, share the ability
to degrade fatty acid chains. Although each organelle harbors its own fatty acid β-oxidation …

Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD),
the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD …

The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in
the hepatocytes, which may be an isolated event (non‐alcoholic fatty liver, NAFL) or …

Therapeutic approaches to metabolic syndrome (MetS) are numerous and may target
lipoproteins, blood pressure or anthropometric indices. Peroxisome proliferator-activated …

Schizophrenia is a very complex syndrome involving widespread brain multi-
dysconnectivity. Schizophrenia is marked by cognitive, behavioral, and emotional …

Understanding of the pathophysiology of atherogenesis has evolved substantially during the
last few decades. Atherosclerosis was once identified as a lipid-storage disease, but is now …

The metabolic syndrome (MetS) is comprised of a cluster of closely related risk factors,
including visceral adiposity, insulin resistance, hypertension, high triglyceride, and low high …

Individuals with type 2 diabetes mellitus have increased cardiovascular disease risk
compared with those without diabetes. Treatment of the residual risk, other than blood …